Q-omics provides the consensus-scored ABHD1 profile across patient tissues and cancer cell-line models. ABHD1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, ABHD1 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, ABHD1 RNA expression shows 17,698 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight COAD, KICH, and LSCC as cancer lineages where ABHD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ABHD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ABHD1 survival associations across molecular data types. ABHD1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ABHD1 RNA expression–survival associations across cancer types. High ABHD1 expression shows unfavorable associations in COAD, CESC and UCEC, but favorable associations in KIRP, BRCA and KIRC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for ABHD1 RNA expression.
This table summarizes ABHD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ABHD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ABHD1 shows lower tumor expression in KICH, THCA and BRCA and higher tumor expression in COAD, KIRC and BLCA. The KICH box plot shows higher ABHD1 RNA expression in normal versus tumor tissue (log2 FC = −0.765, t-test p < 0.001).
This table shows molecular features associated with ABHD1 in patient tissues and cancer cell lines. In patient samples, ABHD1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ABHD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
